{"id":"trastuzumab-injection","safety":{"commonSideEffects":[{"rate":"2-7%","effect":"Cardiotoxicity / left ventricular dysfunction"},{"rate":"20-40%","effect":"Infusion reactions"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-15%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain breast cancers. By binding to HER2, it prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).","oneSentence":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:52.763Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)"},{"name":"HER2-positive gastric cancer"}]},"trialDetails":[{"nctId":"NCT07495930","phase":"PHASE1","title":"A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-30","conditions":"Health Adult Subjects","enrollment":24},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT07497386","phase":"PHASE2","title":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":"Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer","enrollment":150},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT07294508","phase":"PHASE2, PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":"HER2 + Breast Cancer","enrollment":706},{"nctId":"NCT05232916","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","status":"RECRUITING","sponsor":"Greenwich LifeSciences, Inc.","startDate":"2022-08-11","conditions":"Breast Cancer","enrollment":750},{"nctId":"NCT01613482","phase":"PHASE3","title":"TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2008-01","conditions":"Breast Cancer, Metastasis, Sur-expressing Her2-neu","enrollment":13},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06057610","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10-16","conditions":"HER2-PositiveRecurrent or Metastatic Breast Cancer","enrollment":868},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT07214766","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-17","conditions":"Healthy Participants","enrollment":312},{"nctId":"NCT07436858","phase":"PHASE1","title":"Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-08-01","conditions":"Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation","enrollment":20},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":"Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer","enrollment":550},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT06100874","phase":"PHASE2","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2023-11-20","conditions":"Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic","enrollment":28},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518},{"nctId":"NCT04739761","phase":"PHASE3","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-22","conditions":"Breast Cancer","enrollment":506},{"nctId":"NCT07118527","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-18","conditions":"Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":600},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07386938","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-09","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT07196774","phase":"PHASE3","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-23","conditions":"Early-stage or Locally Advanced HER2-positive Breast Cancer","enrollment":740},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT05150691","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-01-31","conditions":"HER2-positive Advanced Solid Tumor","enrollment":796},{"nctId":"NCT03321045","phase":"EARLY_PHASE1","title":"Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2017-11-21","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT06830889","phase":"PHASE3","title":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-03","conditions":"HER2-positive Breast Cancer","enrollment":1450},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT04744831","phase":"PHASE2","title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2021-03-05","conditions":"Advanced Colorectal Cancer","enrollment":122},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT05378464","phase":"PHASE1","title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-05-31","conditions":"HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT07299955","phase":"PHASE1","title":"A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-01-09","conditions":"Healthy Male Participants","enrollment":150},{"nctId":"NCT07299890","phase":"PHASE2","title":"An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT07294534","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-01-27","conditions":"HER2 + Breast Cancer","enrollment":817},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT07176702","phase":"PHASE2","title":"A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-09-30","conditions":"Metastatic PDAC, HER2-positive Status","enrollment":45},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT01373710","phase":"PHASE1, PHASE2","title":"Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2011-05-19","conditions":"Metastatic Breast Cancer, Carcinomatous Meningitis","enrollment":34},{"nctId":"NCT04644237","phase":"PHASE2","title":"Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2021-03-19","conditions":"Non-Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT05800275","phase":"PHASE2","title":"Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-12-18","conditions":"Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":"Metastatic Breast Cancer With a Isolated Brain Progression","enrollment":53},{"nctId":"NCT01093612","phase":"NA","title":"Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-03-16","conditions":"Breast Cancer, Stage IV Breast Cancer","enrollment":18},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT06680596","phase":"PHASE2","title":"Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"UNICANCER","startDate":"2025-07-30","conditions":"Breast Cancer Metastatic, Breast Cancer Stage IV","enrollment":80},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06239467","phase":"PHASE1","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","status":"RECRUITING","sponsor":"OnKure, Inc.","startDate":"2024-02-26","conditions":"Advanced Cancer, Breast Cancer, Advanced Solid Tumors","enrollment":200},{"nctId":"NCT07157956","phase":"PHASE1, PHASE2","title":"CVL006 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2025-09-10","conditions":"Advanced Solid Tumor","enrollment":318},{"nctId":"NCT07086768","phase":"PHASE1","title":"Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Lei Zheng","startDate":"2026-01-01","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":57},{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Breast Cancers","enrollment":112},{"nctId":"NCT06414733","phase":"PHASE1","title":"HER-2 B Cell Peptide Vaccine","status":"RECRUITING","sponsor":"Pravin T.P Kaumaya","startDate":"2025-01-17","conditions":"Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoma, HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT07008976","phase":"PHASE3","title":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-07","conditions":"Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT02003209","phase":"PHASE3","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-02-18","conditions":"HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":315},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":"HER2-positive Breast Cancer","enrollment":165},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT06441890","phase":"PHASE2","title":"BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-05","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT01275677","phase":"PHASE3","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma","enrollment":3270},{"nctId":"NCT07057427","phase":"PHASE3","title":"Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-24","conditions":"Breast Cancer","enrollment":812},{"nctId":"NCT03767335","phase":"PHASE1","title":"MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2018-11-13","conditions":"Advanced or Metastatic Breast Cancer","enrollment":62},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT07003074","phase":"PHASE3","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT06832202","phase":"PHASE2","title":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-16","conditions":"HER2-low Hormone Receptor Positive Breast Cancer","enrollment":50},{"nctId":"NCT05346224","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-04-25","conditions":"Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer","enrollment":900},{"nctId":"NCT01273610","phase":"PHASE2","title":"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-04-20","conditions":"Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services","enrollment":40},{"nctId":"NCT00393783","phase":"PHASE1","title":"Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Breast Cancer","enrollment":13},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT05319873","phase":"PHASE1, PHASE2","title":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-04-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":18},{"nctId":"NCT06126640","phase":"PHASE3","title":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-11-20","conditions":"HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","enrollment":1600},{"nctId":"NCT06837792","phase":"PHASE2","title":"Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-10-01","conditions":"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)","enrollment":141},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT02091960","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-09-05","conditions":"HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)","enrollment":103},{"nctId":"NCT01565200","phase":"PHASE2","title":"HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2012-05","conditions":"HER-2 Positive Breast Cancer","enrollment":90},{"nctId":"NCT05636215","phase":"PHASE1, PHASE2","title":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-04-04","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":368},{"nctId":"NCT05332561","phase":"PHASE2","title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","status":"RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-06-29","conditions":"Early-stage Breast Cancer","enrollment":240},{"nctId":"NCT02488564","phase":"PHASE2","title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2014-12-17","conditions":"HER-2 Positive Breast Cancer","enrollment":49},{"nctId":"NCT02705859","phase":"PHASE1","title":"Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2016-04","conditions":"HER2 Positive Breast Cancer","enrollment":26},{"nctId":"NCT05414136","phase":"PHASE1","title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-02-10","conditions":"Advanced Solid Tumor","enrollment":37},{"nctId":"NCT06276868","phase":"PHASE2","title":"Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-01-20","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":71},{"nctId":"NCT06718335","phase":"NA","title":"Pyrotinib in HER2-positive Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nie Jianyun","startDate":"2024-12-30","conditions":"HER2-positive Breast Cancer","enrollment":156},{"nctId":"NCT02023996","phase":"NA","title":"PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-12","conditions":"Esophagogastric Cancer","enrollment":42},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT01957332","phase":"NA","title":"IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2013-08-30","conditions":"Metastatic Breast Cancer","enrollment":217},{"nctId":"NCT05965479","phase":"PHASE2","title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2024-04-10","conditions":"Gastrooesophageal Cancer","enrollment":25},{"nctId":"NCT05275010","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-30","conditions":"Healthy Male Subjects","enrollment":151},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"HYPOKALAEMIA"},{"count":2,"reaction":"NAUSEA"},{"count":1,"reaction":"ABASIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"CANDIDIASIS"},{"count":1,"reaction":"CELLULITIS"},{"count":1,"reaction":"COORDINATION ABNORMAL"}],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin"],"phase":"phase_3","status":"active","brandName":"Trastuzumab Injection","genericName":"Trastuzumab Injection","companyName":"Spanish Breast Cancer Research Group","companyId":"spanish-breast-cancer-research-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab Injection is an antibody that inhibits the receptor tyrosine-protein kinase erbB-2, a receptor protein-tyrosine kinase. It is used to treat conditions such as Advanced HER2-positive Breast Cancer and HER2-positive Breast Cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}